Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31 mai 2024 01h05 HE
|
Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
31 mai 2024 01h00 HE
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
28 mai 2024 07h00 HE
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...
Dr. Nooristani Announces Breakthrough Solution for Combatting Acidosis
21 mai 2024 09h00 HE
|
Balance7
Santa Maria , May 21, 2024 (GLOBE NEWSWIRE) -- Are you aware of the silent threat acidosis poses to your health? Acidosis, an imbalance in the body's pH levels, can lead to serious health issues...
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
09 mai 2024 07h30 HE
|
Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
01 mai 2024 08h00 HE
|
ImmuneSensor Therapeutics
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...
Discover Dr. Nooristani's Insights: Announcement for National Stress Awareness Month
18 avr. 2024 08h00 HE
|
Balance7
Santa Maria , April 18, 2024 (GLOBE NEWSWIRE) -- Discover the profound impact of stress on your health during National Stress Awareness Month this April. Uncover the intricate link between...
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
16 avr. 2024 07h14 HE
|
Arch Biopartners
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a...
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
09 avr. 2024 07h00 HE
|
Nurix Therapeutics, Inc.
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within...
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14 mars 2024 07h57 HE
|
ZyVersa Therapeutics
Mr. Glover will talk about inflammasomes, and how they trigger development and spread of damaging inflammation, the culprit behind many deadly diseases.